BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price objective boosted by research analysts at JMP Securities from $12.00 to $16.00 in a report issued on Wednesday, The Fly reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. JMP Securities’ price objective would suggest a potential upside of 103.82% from the stock’s current price.
BCRX has been the subject of a number of other reports. BidaskClub downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 15th. Seaport Global Securities reiterated a “neutral” rating on shares of BioCryst Pharmaceuticals in a research report on Thursday, June 28th. ValuEngine upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, August 8th. Royal Bank of Canada reiterated a “buy” rating and set a $9.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 7th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $8.50 target price on shares of BioCryst Pharmaceuticals in a research report on Thursday, August 9th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. BioCryst Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $9.57.
Shares of NASDAQ BCRX traded down $0.14 during midday trading on Wednesday, reaching $7.85. 3,826 shares of the stock traded hands, compared to its average volume of 758,127. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.25 and a current ratio of 1.25. The company has a market capitalization of $783.18 million, a P/E ratio of -10.13 and a beta of 1.68. BioCryst Pharmaceuticals has a one year low of $4.12 and a one year high of $8.01.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.05. The firm had revenue of $12.49 million during the quarter, compared to the consensus estimate of $3.80 million. BioCryst Pharmaceuticals had a negative return on equity of 107.85% and a negative net margin of 270.95%. equities analysts predict that BioCryst Pharmaceuticals will post -0.86 EPS for the current fiscal year.
In related news, CMO William P. Sheridan sold 62,500 shares of the stock in a transaction on Thursday, August 9th. The stock was sold at an average price of $7.03, for a total transaction of $439,375.00. Following the sale, the chief marketing officer now owns 85,713 shares in the company, valued at approximately $602,562.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 5.21% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in BCRX. Janus Henderson Group PLC raised its holdings in BioCryst Pharmaceuticals by 45.0% during the 2nd quarter. Janus Henderson Group PLC now owns 11,096,183 shares of the biotechnology company’s stock valued at $63,581,000 after buying an additional 3,441,498 shares during the period. Citadel Advisors LLC increased its stake in BioCryst Pharmaceuticals by 4,343.1% in the first quarter. Citadel Advisors LLC now owns 462,079 shares of the biotechnology company’s stock worth $2,204,000 after purchasing an additional 451,679 shares during the period. BlackRock Inc. increased its stake in BioCryst Pharmaceuticals by 3.8% in the second quarter. BlackRock Inc. now owns 7,755,951 shares of the biotechnology company’s stock worth $44,442,000 after purchasing an additional 281,532 shares during the period. VHCP Management II LLC increased its stake in BioCryst Pharmaceuticals by 11.0% in the second quarter. VHCP Management II LLC now owns 2,464,241 shares of the biotechnology company’s stock worth $14,120,000 after purchasing an additional 243,270 shares during the period. Finally, UBS Group AG increased its stake in BioCryst Pharmaceuticals by 190.7% in the first quarter. UBS Group AG now owns 291,379 shares of the biotechnology company’s stock worth $1,390,000 after purchasing an additional 191,157 shares during the period. Institutional investors own 80.24% of the company’s stock.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Recommended Story: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.